Provider review
Gala Health review
A named microdose tier, nationwide — but every published rate is a yearly one.
It prices the low tier below the standard one, then puts both behind the same yearly subscription.
Price as published
$149/mo microdose tirzepatide and $179/mo standard compounded, both on a yearly subscription · $199/mo on a 3-month plan · brand Ozempic from $1,299/mo · no month-to-month rate published
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The verdict
Gala Health prices a compounded microdose tirzepatide tier below its standard tier, which is the behaviour this site is looking for — a lower dose that actually costs less rather than the same. The catch is the term, not the number: the headline rate is printed directly above the words "yearly subscription", the microdose tier carries that same commitment, and no month-to-month price appears anywhere on the site, so the low figure is not a rate you can buy by the month. It prices in public rather than behind a quiz, prescribes in all 50 states, and keeps a brand-name pathway open. It is also injectable only, so a small dose means drawing a partial unit, and it names neither the pharmacy filling it nor a single clinician.
The trade-off we would want you to read first
⚠ Every published rate is a yearly subscription — the $179 headline is printed above "All doses included. Yearly subscription" and the $149 microdose tier carries the same term, so the low figure is not a monthly price you can actually buy by the month
Who it suits, and who it does not
A good fit if
- Tirzepatide is the molecule you want and you intend to stay at a low dose
- You are ready to commit to a year — that is the only term its prices are quoted on
- You are in a state that narrows your options — it prescribes in all 50
- You want the option of moving to a brand-name product later without changing provider
Look elsewhere if
- You want to pay month to month: no monthly rate is published at any tier
- You want a needle-free route: there is no oral or sublingual option
- You want to know which pharmacy fills the vial, or which clinician signs the prescription
- You are not who it is written for — it is marketed throughout as a women's brand
How the programme works
An online intake is reviewed by Gala's clinical team (AI Coaching, Inc., with care delivered through OpenLoop-affiliated medical groups), then compounded semaglutide or tirzepatide is shipped to you. The prices are public rather than quiz-gated, which is worth something on this board — but every one of them is a yearly commitment: the $179/mo headline sits directly above the words "All doses included. Yearly subscription", the $149/mo microdose tier carries the same term, and the shortest plan quoted anywhere is $199/mo over three months. Gala is LegitScript-verified, markets itself as a women's brand ("dosed for women's bodies"), states all 50 states without publishing a list, and runs a full HRT/menopause line beside the metabolic one. A brand-name pathway (Ozempic from $1,299/mo) sits alongside the compounded arm.
At a glance
- Pricing structure
- Varies by dose, plan or tier
- Consult
- Included in the price
- Compounding
- Network
- Labs
- Optional
- Dietitian support
- Not included
Strengths
- A microdose tirzepatide tier priced BELOW the standard tier at $149/mo — the structure this board is looking for, if you can commit to a year
- Prices are published openly rather than held behind an intake quiz, so a plan can be costed before you sign up
- Prescribes in all 50 states — one of the widest footprints in this list
- Offers a brand-name GLP-1 pathway in addition to compounded, so patients can switch tracks
- Adjacent HRT/menopause care for patients combining metabolic and hormone treatment
The other trade-offs
- Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven
- The brand-name pathway (from $1,299/mo) is far pricier than the compounded microdose tier
- No oral/sublingual option yet — injectable only, so a small dose means drawing a partial unit
- Neither the dispensing pharmacy (only "a wide network") nor a single clinician is named, by a newer operator with a short public record
Before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomised trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Where this sits on the board
Gala Health is one of 32 low-dose GLP-1 providers we track. The board lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Funding & disclosures
- A number of links are affiliate or referral links.
- Begin treatment through one and we may earn a commission via the Katalys network — at no added cost to you.
- What we write about a provider is the same either way — unflattering findings about one that pays us stay in.
- Full detail: disclosure page.